157 related articles for article (PubMed ID: 25270152)
21. Use of monoclonal antibodies in renal transplantation.
van den Hoogen MW; Hilbrands LB
Immunotherapy; 2011 Jul; 3(7):871-80. PubMed ID: 21751955
[TBL] [Abstract][Full Text] [Related]
22. Isoagglutinin adsorption in ABO-incompatible transplantation.
Genberg H; Kumlien G; Wennberg L; Tydén G
Transfus Apher Sci; 2010 Oct; 43(2):231-5. PubMed ID: 20667787
[TBL] [Abstract][Full Text] [Related]
23. Rituximab induction therapy in highly sensitized kidney transplant recipients.
Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
[TBL] [Abstract][Full Text] [Related]
24. Abrogation of antibodies improves outcome of renal transplantation.
Trivedi HL; Vanikar AV; Gumber MR; Patel HV; Shah PR; Kute VB
Transplant Proc; 2012 Jan; 44(1):241-7. PubMed ID: 22310623
[TBL] [Abstract][Full Text] [Related]
25. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
26. Co-signals in organ transplantation.
Durrbach A; Francois H; Jacquet A; Beaudreuil S; Charpentier B
Curr Opin Organ Transplant; 2010 Aug; 15(4):474-80. PubMed ID: 20631615
[TBL] [Abstract][Full Text] [Related]
27. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction.
Fuchinoue S; Ishii Y; Sawada T; Murakami T; Iwadoh K; Sannomiya A; Koyama I; Kubota K; Tojimbara T; Nakajima I; Teraoka S
Transplantation; 2011 Apr; 91(8):853-7. PubMed ID: 21297552
[TBL] [Abstract][Full Text] [Related]
28. The clinical application of monoclonal antibody therapies in renal transplantation.
Dhanireddy KK; Xu H; Mannon RB; Hale DA; Kirk AD
Expert Opin Emerg Drugs; 2004 May; 9(1):23-37. PubMed ID: 15155134
[TBL] [Abstract][Full Text] [Related]
29. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
[TBL] [Abstract][Full Text] [Related]
30. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
Ravichandran P; Natrajan T; Jaganathan R
Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the acute rejection incidence rate in spousal donor transplantation before and after anti-CD20 antibody (rituximab) protocol as desensitization therapy.
Hirai T; Ishida H; Toki D; Miyauchi Y; Kohei N; Iida S; Tokita D; Shimizu T; Shirakawa H; Omoto K; Tanabe K
Ther Apher Dial; 2011 Feb; 15(1):89-97. PubMed ID: 21272258
[TBL] [Abstract][Full Text] [Related]
32. [Immunosuppression after organ transplantation].
Wagner K; Erhard J
Zentralbl Chir; 1992; 117(12):648-52. PubMed ID: 1285470
[TBL] [Abstract][Full Text] [Related]
33. Influence of preoperative anti-HLA antibodies on short- and long-term graft survival in recipients with or without rituximab treatment.
Ishida H; Furusawa M; Shimizu T; Nozaki T; Tanabe K
Transpl Int; 2014 Apr; 27(4):371-82. PubMed ID: 24438437
[TBL] [Abstract][Full Text] [Related]
34. The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in ABO-incompatible kidney transplantation.
Genberg H; Kumlien G; Wennberg L; Tyden G
Nephrol Dial Transplant; 2011 Jul; 26(7):2394-400. PubMed ID: 21558429
[TBL] [Abstract][Full Text] [Related]
35. [The role of polyclonal anti-T-lymphocyte antibodies (ATG) in the kidney transplantation].
Nikolovski M; Kotsev Iu; Dimitrov S; Nikolova M; Panchev P
Khirurgiia (Sofiia); 2004; 60(4-5):42-5. PubMed ID: 16042064
[TBL] [Abstract][Full Text] [Related]
36. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
[TBL] [Abstract][Full Text] [Related]
37. Update on the role of rituximab in kidney diseases and transplant.
Ramanath V; Nistala R; Chaudhary K
Expert Opin Biol Ther; 2012 Feb; 12(2):223-33. PubMed ID: 22188359
[TBL] [Abstract][Full Text] [Related]
38. Kinetics of functionally distinct T-lymphocyte subsets in heart transplant recipients after induction therapy with anti-CD25 monoclonal antibodies.
Lanio N; Sarmiento E; Gallego A; Navarro J; Palomo J; Fernandez-Yañez J; Ruiz M; Fernandez-Cruz E; Carbone J
Transpl Immunol; 2013 Jun; 28(4):176-82. PubMed ID: 23611763
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
